SCHEMBL4563571

SCHEMBL4563571

CC(C)(C)OC(=O)N1CCN(c2ccc(NC(=O)C3CCCC3)cc2F)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
MAPT P10636 3/20 0.60
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
PTPN2 P17706 1/20 0.58
PTPN1 P18031 1/20 0.58
PTPN6 P29350 1/20 0.58
NPY2R P49146 3/20 0.54
ABL1 P00519 1/20 0.54
RIN1 Q13671 1/20 0.54
ALDH1A1 P00352 4/20 0.49
HPGD P15428 2/20 0.49
F13A1 P00488 1/20 0.49
TGM2 P21980 1/20 0.49
TGM1 P22735 1/20 0.49
TSHR P16473 1/20 0.49
KDM4E B2RXH2 2/20 0.48
HSD17B10 Q99714 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6115381 0.88 NPY2R (0.57) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL13532985 0.87 MAPT (0.50) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL13532987 0.86 SCN9A (0.51) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL13541856 0.86 NPC1 (0.50) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL8250828 0.85 F13A1 (0.53) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL5421815 0.85 NPY2R (0.55) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL7846281 0.85 F13A1 (0.53) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL13532990 0.85 NPC1 (0.56) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL8259530 0.84 NPY2R (0.56) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL4004656 0.83 F13A1 (0.50) MEN1KMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129870-A1 PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 US disclosed
WO-2009079597-A1 PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129870-A1 PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR NPY2R, NPY1R, NPY5R MEN1 2747/4885KMT2A 3083/4885MAPT 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.